News | July 02, 2022
Lonza to invest 500 mn in commercial drug product fill & finish facility
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
Subscribe To Our Newsletter & Stay Updated
